Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2022

Open Access 01-12-2022 | Migraine | Research

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients

Authors: Marina de Tommaso, Marianna La Rocca, Silvia Giovanna Quitadamo, Katia Ricci, Giusy Tancredi, Livio Clemente, Eleonora Gentile, Elena Ammendola, Marianna Delussi

Published in: The Journal of Headache and Pain | Issue 1/2022

Login to get access

Abstract

Background

The discovery of the prominent action of Calcitonin Gene Related Peptide –CGRP- on trigeminal afferents and meningeal vessels, opened a new era in migraine treatment. However, how the block of nociceptive afferents could act on central mechanisms of migraine is still not clear. In this pilot study we aimed to test the effect of 3 months Galcanezumab (CGA) therapy on occipital visual reactivity in migraine patients, using the Steady State Visual Evoked Potentials-SSVEPs and Functional Near Infrared Spectroscopy –fNIRS.

Method

Thirteen migraine patients underwent clinical and neurophysiological examination in basal condition (T0), 1 h after GCA injection (T1) and after 3 months of GCA treatment (T2). Ten healthy volunteers were also evaluated.

Results

At T2, there was a reduction of headache frequency and disability. At T2, the EEG power significantly diminished as compared to T0 and T1 at occipital sites, and the topographical analysis confirmed a restoration of SSVEPs within normal values. The Oxyhemoglobin levels in occipital cortex, which were basically increased during visual stimulation in migraine patients, reverted to normal values at T2.

Conclusions

The present pilot study indicates that Galcanezumab could act on cortical targets located beyond the pain network, restoring the abnormal occipital reactivity. This effect could indicate the possible disease modifying properties of CGRP related monoclonal antibodies.
Literature
1.
Edvinsson L, Haanes KA, Warfvinge K et al (2028) CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 14:338–350CrossRef
2.
Iyengar S, Johnson KW, Ossipov MH et al (2019) CGRP and the trigeminal system in migraine. Headache 59:659–681CrossRef
3.
Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL (2021) Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials. Adv Ther 38(3):1614–1626CrossRef
4.
Goadsby PJ, Reuter U, Lanteri-Minet M et al (2021) Long-term Efficacy and Safety of Erenumab Results From 64 Weeks of the LIBERTY Study. Neurology 96(22):e2724–e2735CrossRef
5.
de Tommaso M, Delussi M, Gentile E, Ricci K, Quitadamo SG, Libro G (2021) Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients. Cephalalgia 41(9):1004–1014CrossRef
6.
Ziegeler C, Mehnert J, Asmussen K, May A (2020) Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology 17;95(20):e2794–e2802CrossRef
7.
Blumenfeld A, Durham PL, Feoktistov A, Hay DL, Russo AF, Turner I (2021) Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor. Neurol Ther 10(2):469–497CrossRef
8.
Lau CI, Chen WH, Walsh V (2020) The visual system as target of non-invasive brain stimulation for migraine treatment: Current insights and future challenges. Prog Brain Res 255:207–247CrossRef
9.
de Tommaso M (2019) An update on EEG in migraine Expert Rev Neurother 19(8):729–737CrossRef
10.
Mehnert J, Bader D, Nolte G, May A (2019) Visual input drives increased occipital responsiveness and harmonized oscillations in multiple cortical areas in migraineurs. Neuroimage Clin 23:101815CrossRef
11.
Shibata K, Yamane K, Otuka K, Iwata M (2008) Abnormal visual processing in migraine with aura: a study of steady-state visual evoked potentials. J Neurol Sci 271(1-2):119–126CrossRef
12.
de Tommaso M, Trotta G, Vecchio E, Ricci K, Siugzdaite R, Stramaglia S (2017) Brain networking analysis in migraine with and without aura. J Headache Pain 18(1):98CrossRef
13.
Asghar MS, Hansen AE, Larsson HB, Olesen J, Ashina M (2012) Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain 13(2):159–166CrossRef
14.
Chen WL, Wagner J, Heugel N et al (2020) (2020) Functional Near-Infrared Spectroscopy and Its Clinical Application in the Field of Neuroscience: Advances and Future Directions. Front Neurosci 14:724CrossRef
15.
Nikulin VV, Fedele T, Mehnert J, Lipp A, Noack C, Steinbrink J, Curio G (2014) Monochromatic ultra-slow (~0.1 Hz) oscillations in the human electroencephalogram and their relation to hemodynamics. Neuroimage 97:71–80CrossRef
16.
Coutts LV, Cooper CE, Elwell CE, Wilkins AJ (2012) Time course of the haemodynamic response to visual stimulation in migraine, measured using near-infrared spectroscopy. Cephalalgia 32(8):621–629CrossRef
17.
Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd ed. Cephalalgia 38(1):1–211
18.
de Tommaso M, Delussi M (2018) Circadian rhythms of migraine attacks in episodic and chronic patients: a cross sectional study in a headache center population. BMC Neurol 18(1):94CrossRef
19.
D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, Leone M, Puca FM, Bussone G (2001) The Migraine Disability Assessment (MIDAS) Questionnaire: Translation and Reliability of the Italian Version. Cephalalgia 21(10):947–952CrossRef
20.
Gratton G, Coles MG, Donchin E (1983) A new method for off-line removal of ocular artifact. Electroencephalogr Clin Neurophysiol 55(4):468–484CrossRef
21.
Gramfort A, Luessi M, Larson E et al (2013) MEG and EEG data analysis with MNE-Python. Front Neurosci 7(267):1–13
22.
Fishburn FA, Ludlum RS, Vaidya CJ, Medvedev AV (2019) Temporal derivative distribution repair (tddr): a motion correction method for fNIRS. NeuroImage 184:171–179CrossRef
23.
Julien C (2006) The enigma of Mayer waves: Facts and models. Cardiovasc Res 70(1):12–21CrossRef
24.
Obrig H, Neufang M, Wenzel R, Kohl M, Steinbrink J, Einhäupl K, Villringer A (2000) Spontaneous low frequency oscillations of cerebral hemodynamics and metabolism in human adults. Neuroimage 12(6):623–639CrossRef
25.
Baker WB, Parthasarathy AB, Busch DR, Mesquita RC, Greenberg JH, Yodh AG (2014) Modified Beer-Lambert law for blood flow. Biomed Opt Exp 5(11):4053–4075CrossRef
26.
de Tommaso M, Ambrosini A, Brighina F et al (2014) (2014) Altered processing of sensory stimuli in patients with migraine. Nat Rev Neurol 10(3):144–155CrossRef
27.
de Tommaso M, Marinazzo D, Nitti L, Pellicoro M, Guido M, Serpino C, Stramaglia S (2007) Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clin Neurophysiol 118(10):2297–2304CrossRef
28.
de Tommaso M, Stramaglia S, Schoffelen JM et al (2003) Steady-state visual evoked potentials in the low frequency range in migraine: a study of habituation and variability phenomena. Int J Psychophysiol 49:165–174CrossRef
29.
Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 22(1):15CrossRef
30.
Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F, Strassman AM, Burstein R (2020) Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40(3):229–240CrossRef
31.
Huang J, Cao Y (2012) Functional MRI as a biomarker for evaluation and prediction of effectiveness of migraine prophylaxis. Biomark Med 6(4):517–527CrossRef
32.
Christensen SL, Ernstsen C, Olesen J, Kristensen DM (2020) No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Cephalalgia. 40(9):924–934CrossRef
33.
Warfvinge K, Edvinsson L, Pickering DS, Sheykhzade M (2019) The Presence of Calcitonin Gene-Related Peptide and Its Receptors in Rat, Pig and Human Brain: Species Differences in Calcitonin Gene-Related Peptide Pharmacology. Pharmacology 104(5-6):332–341CrossRef
34.
González-Hernández A, Marichal-Cancino BA, García-Boll E, Villalón CM (2020) The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms. CNS Neurol Disord Drug Targets 19(5):344–359CrossRef
35.
Chiarugi A (2019) A Popperian view on anti-CGRP biologics in migraine. Headache J Head Face Pain 59:1855–1860CrossRef
36.
37.
Garcia-Larrea L, Frot M, Valeriani M (2003) Brain generators of laser-evoked potentials: from dipoles to functional significance. Neurophysiol Clin 33(6):279–292CrossRef
38.
Russo A, Tessitore A, Silvestro M et al (2019) Advanced visual network and cerebellar hyperresponsiveness to trigeminal nociception in migraine with aura. J Headache Pain 20(1):46CrossRef
39.
40.
Chen WL, Wagner J, Heugel N et al (2020) Functional Near-Infrared Spectroscopy and Its Clinical Application in the Field of Neuroscience: Advances and Future Directions. Front Neurosci 14:724CrossRef
Metadata
Title
Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
Authors
Marina de Tommaso
Marianna La Rocca
Silvia Giovanna Quitadamo
Katia Ricci
Giusy Tancredi
Livio Clemente
Eleonora Gentile
Elena Ammendola
Marianna Delussi
Publication date
01-12-2022
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-022-01421-z

Other articles of this Issue 1/2022

The Journal of Headache and Pain 1/2022 Go to the issue

Review article

Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies

Research article

Effectiveness and acceptability of noninvasive brain and nerve stimulation techniques for migraine prophylaxis: a network meta-analysis of randomized controlled trials

Case report

Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series

Research article

IL-17 crosses the blood–brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine

Author Correction

Correction: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan

Research

Enhanced pain facilitation rather than impaired pain inhibition in burning mouth syndrome female patients